 | Up a level |
Journal Article
Borgmann, H., Salem, J., Cebulla, A., Ralla, B., Busch, J. and Miller, K. (2016). German Society of Urology- Congress and Social Media: Hands-on, Interaction, and Discussion. Urologe, 55 (7). S. 966 - 968. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Chowdhury, S., Shore, N., Saad, F., Higano, C. S., Fizazi, K., Iversen, P., Miller, K., Heidenreich, A., Ueda, T., Kim, C. S., Phung, D., Krivoshik, A., Wang, F., Wu, K. and Tombal, B. (2016). Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Heidenreich, A., Carl, S., Feyerabend, S., Gleissner, J., Gruellich, C., Heinrich, B., Merseburger, A., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Go, J., Golsorkhi, T., Abida, W. and Scher, H. I. (2018). TRITON2: An International, Multicentre, Open-Label Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 75 - 76. BASEL: KARGER. ISSN 2296-5262
Heidenreich, A., O'Sullivan, J., Gillessen, S., Heinrich, D., Gratt, J., Levy, J., Miller, K., Nilson, S., Saad, F., Tucci, M., Wirth, M. and Carles, J. (2016). Effects of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration resistant prostate cancer (mCRCP) patients treated in an international early access program (EAP). Oncol. Res. Treat., 39. S. 86 - 88. BASEL: KARGER. ISSN 2296-5262
Heidenreich, A., Saad, F., Caries, J., Gillessen, S., Heinrich, D., Gratt, J., Miller, K., Nilsson, S., O'Sullivan, J., Tucci, M. and Wirth, M. (2016). Effects of concomitant medication and baseline parameters on overall survival and safety in German metastatic castration-resistant prostate cancer patient subset treated with Radium-223 dichloride within the international early access program (iEAP). Oncol. Res. Treat., 39. S. 268 - 269. BASEL: KARGER. ISSN 2296-5262
Heinrich, D., Gillessen, S., Heidenreich, A., Keizman, D., O'Sullivan, J. M., Carles, J., Wirth, M., Miller, K., Procopio, G., Gratt, J., Seger-Van Tol, M., Nilsson, S. and Saad, F. (2016). Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Merseburger, A., Carl, S., Feyerabend, S., Gleissner, J., Grimm, M. -O., Gruellich, C., Heidenreich, A., Heinrich, B., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Passler, L., Shetty, S., Golsorkhi, T., Ryan, C. and Chowdhury, S. (2018). TRITON3: An International, Randomised, Open-Label Phase 3 Study of the PARP Inhibitor Rucaparib vs Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associate with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 74 - 75. BASEL: KARGER. ISSN 2296-5262
Miller, K., Albers, P., Eichenauer, R., Geiges, G., Grimm, M-O., Koenig, F., Mickisch, G., Pfister, D., Schwentner, C., Suttmann, H. and Zastrow, S. (2016). Metastatic castration-resistant prostate cancer. Clinical data, new treatment options and therapy monitoring. Urologe, 55 (9). S. 1206 - 1213. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Miller, K., Heinrich, D., O'Sullivan, J. M., Carles, J., Wirth, M., Nilsson, S., Huang, L., Kalinovsky, J., Heidenreich, A. and Saad, F. (2018). Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 29. S. 287 - 288. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Oezistanbullu, D., Kluemper, N., Humke, C., Salem, J., Borgmann, H. and Miller, K. (2017). The Best for Urology grant - first steps in a fascinating specialty. Urologe, 56 (3). S. 387 - 390. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Saad, F., Heidenreich, A., Heinrich, D., Keizman, D., O'Sullivan, J. M., Carles, J., Wirth, M., Miller, K., Gratt, J., Seger-Van Tol, M., Nilsson, S. and Gillessen, S. (2016). Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Smith, M. R., Parker, C. C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., Boegemann, M., Matveev, V., Piulats, J. M., Zucca, L. E., Heidenreich, A., Kakehi, Y., Zhang, A., Krissel, H., Shen, J., Wagner, V. and Higano, C. (2018). ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Zastrow, S., Saad, F., Heinrich, D., Gillessen, S., OSullivan, J., Carles, J., Miller, K., Huang, L., Van Tol, Seeger M., Nilsson, S. and Heidenreich, A. (2017). Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP). Oncol. Res. Treat., 40. S. 94 - 95. BASEL: KARGER. ISSN 2296-5262